ZIMV
Company Description
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Track Record
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 449.75M | 457.43M | 913.86M | 1.01B | 912.40M | 1.06B | 1.10B |
| Net Income | (25.82M) | (393.28M) | (63.88M) | (95.30M) | (179.00M) | (27.90M) | (460.40M) |
| EPS | -0.94 | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| Free Cash Flow | 7.49M | 24.66M | (1.92M) | 7.70M | 47.70M | 66.20M | 113.70M |
| FCF / Share | 0.27 | 0.93 | -0.07 | 0.30 | 1.83 | 2.54 | 4.36 |
| Operating CF | 14.17M | 37.15M | 24.63M | 64.30M | 86.00M | 119.20M | 162.00M |
| Total Assets | 753.67M | 1.21B | 1.64B | 1.83B | 1.95B | 2.11B | N/A |
| Total Debt | 232.57M | 521.93M | 564.14M | 57.90M | 89.20M | 86.00M | N/A |
| Cash & Equiv | 74.97M | 71.51M | 89.60M | 100.40M | 27.40M | 37.00M | N/A |
| Book Value | 381.71M | 409.49M | 758.60M | 1.45B | 1.49B | 1.67B | N/A |
| Return on Equity | -0.07 | -0.96 | -0.08 | -0.07 | -0.12 | -0.02 | N/A |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.66M | 112.00M | 111.52M | 103.22M | 116.81M | 118.19M | 113.07M | 202.87M | 224.90M | 225.43M | 229.12M | 214.58M |
| Net Income | (3.95M) | (1.47M) | (11.77M) | (2.28M) | (4.01M) | (7.76M) | (334.85M) | (5.09M) | (23.37M) | (29.97M) | (30.34M) | 831,000 |
| EPS | -0.14 | -0.05 | -0.43 | -0.08 | -0.15 | -0.29 | -12.37 | -0.19 | -0.89 | -1.14 | -1.16 | 0.03 |
| Free Cash Flow | 1.65M | (15.41M) | 18.76M | 615,000 | 1.78M | (13.66M) | 18.65M | 18.06M | (1.01M) | (11.03M) | (14.29M) | (6.05M) |
| FCF / Share | 0.06 | -0.56 | 0.68 | 0.02 | 0.06 | -0.50 | 0.69 | 0.68 | -0.04 | -0.42 | -0.55 | -0.23 |
| Operating CF | 3.23M | (13.91M) | 21.45M | 1.20M | 3.04M | (11.51M) | 21.45M | 22.63M | 256,000 | (7.20M) | (8.90M) | 2.85M |
| Total Assets | 758.22M | 745.78M | 753.67M | 782.95M | 789.79M | 1.17B | 1.21B | 1.51B | 1.56B | 1.59B | 1.64B | 1.63B |
| Total Debt | 234.54M | 232.71M | 232.57M | 234.20M | 249.20M | 522.56M | 521.93M | 543.02M | 549.53M | 552.27M | 564.14M | 582.67M |
| Cash & Equiv | 70.18M | 66.75M | 74.97M | 66.81M | 78.60M | 43.53M | 71.51M | 75.45M | 66.21M | 66.41M | 89.60M | 116.01M |
| Book Value | 412.80M | 395.12M | 381.71M | 406.64M | 394.10M | 388.33M | 409.49M | 710.20M | 727.84M | 743.60M | 758.60M | 733.78M |
| Return on Equity | -0.01 | -0.00 | -0.03 | -0.01 | -0.01 | -0.02 | -0.82 | -0.01 | -0.03 | -0.04 | -0.04 | 0.00 |